SecBot SecBot

LGND

LIGAND PHARMACEUTICALS INC
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000886163 Biotech & Drug Discovery
$308.79 −7.48 (−2.37%)
Nov 13 4:00 PM ET · prev $316.27
Market cap
$6.3B
Mid cap
Consensus
Buy
94% Buy or better · 17 analysts
Median target
$350.00
+13% · range $335.00–406.00
1 year
+53.4%
from $201.35 · Nov 17
30 days
+3.9%
from $297.28
52-week range
$181.65–322.75
−4% from high · low Feb 12
Avg volume 20D
213.3K
shares / day
Short interest
2.46M
≈12.3% of shares · −1.5%
Days to cover
10.5
at average volume
Insider net
−$17.9M
since Aug 12 · excl. 1 subscriber-only trade
New fund stakes
2
Q3 2026 13F · 0 exits
Filing reports
28
analyzed by SecBot
SecBot read MIXED 20 reports · 90 days
Balance 0 bearish · 2 bullish · 1 mixed · 17 neutral oldest → newest, height = score
Avg score ·High conf. 15/20 ·Next FDA decision date, Feb 28, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    5 insiders sold $17.9M. Excludes 1 subscriber-only trade.

  • InstitutionsBULLISH

    Q3 2026: 28 added (2 new), 14 trimmed or exited. Largest new: William Blair Investment Management $37.3M, Hrt Financial $27.9M.

  • AnalystsBULLISH

    16 of 17 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −1.5% to 2.46M shares. 10.5 days to cover, ≈12.3% of shares.

  • TrendUPTREND

    2% above its 50-day average.

Who's buying

13F· Q3 2026
2
new positions
0
exits
$65.2M
in new stakes
FundMoveSharesValue
Invesco Ltd.ADD1,503,709$469.7M
Neuberger Berman Group LLCADD358,478$112.0M
UBS Group AGADD171,184$53.5M
Russell Investments Group, Ltd.ADD170,089$53.1M
VICTORY CAPITAL MANAGEMENT INCTRIM151,895$47.4M
CITIGROUP INCADD129,988$40.6M
BNP PARIBAS FINANCIAL MARKETSADD127,802$39.9M
PRINCIPAL FINANCIAL GROUP INCADD126,842$39.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 94% rate it Buy or better
Strong Buy7Buy9Hold1Sell0Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +13%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 11, 2026Barclays
MAINTAIN
MAINTAINOverweight
Nov 5, 2026Citigroup
MAINTAIN
MAINTAINBuy
Oct 30, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Sep 25, 2026Barclays
INITIATE
INITIATEOverweight
Sep 24, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 23, 2026Citigroup
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$17.9M
sold · 5 insiders · excl. 1 subscriber-only trade
DateInsiderTypeValue
Nov 12, 2026🔒 Fresh data, subscribers only
Nov 12, 2026
SELL
Nov 10, 2026
Aryeh Jason
Director
Nov 10, 2026
SELL$160.1K
Nov 10, 2026
Aryeh Jason
Director
Nov 10, 2026
SELL$160.0K
Nov 10, 2026
Aryeh Jason
Director
Nov 10, 2026
SELL$270.1K
Nov 10, 2026
Aryeh Jason
Director
Nov 10, 2026
SELL$206.7K
Nov 10, 2026
Aryeh Jason
Director
Nov 10, 2026
SELL$3.2K
Nov 10, 2026
Aryeh Jason
Director
Nov 10, 2026
SELL$160.1K
Nov 4, 2026
Aryeh Jason
Director
Nov 4, 2026
SELL$90.2K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$2.36$2.31–$2.41+2.5%$76.1M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Congressional trades
LGND trades disclosed by members of Congress, with disclosure delay.
1 members · 4 buys / 0 sells
DateMemberType AmountDisclosed
May 29, 2026 Gilbert CisnerosDHouse Ligand Pharmaceuticals Inc BUY $1K–$15K Jun 8, 2026 +10d
Mar 3, 2026 Gilbert CisnerosDHouse Ligand Pharmaceuticals Inc BUY $1K–$15K Apr 7, 2026 +35d
Jan 15, 2026 Gilbert CisnerosDHouse Ligand Pharmaceuticals Inc BUY $1K–$15K Feb 13, 2026 +29d
Jan 5, 2026 Gilbert CisnerosDHouse Ligand Pharmaceuticals Inc BUY $1K–$15K Feb 13, 2026 +39d

Short side

FINRA· Oct 30, 2026
2,464,093
shares short
-1.5%
vs prior settlement
10.5
days to cover
≈12.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Director Martine Zimmermann filed a Form 144 notice of intent to sell 2,000 shares of Ligand Pharmaceuticals common…
144 · Impact 2/10
Nov 12, 2026 Insider
🔒 Fresh data, subscribers only
Nov 10, 2026 Insider
Aryeh Jason sold 500 shares
Director @ $320.10 ($160.1K)
Nov 10, 2026 Insider
Aryeh Jason sold 500 shares
Director @ $319.99 ($160.0K)
Oct 29, 2026 Earnings
Ligand Reports Third Quarter 2026 Financial Results
Ligand Reports Third Quarter 2026 Financial Results
Sep 30, 2026 Inst.
Invesco Ltd. · ADD
1,503,709 shares ($469.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
6 drugs tracked · Drug pipeline →
Upcoming
Recent
Oct 29, 2026
Earnings
Ligand Reports Third Quarter 2026 Financial Results
Ligand Reports Third Quarter 2026 Financial Results
Oct 29, 2026
Earnings result
LGND Q3 2026 Earnings: EPS $2.67 (+9.9% vs est)
Oct 27, 2026
Press release
Ligand to Participate in November Investor Conferences
Ligand to Participate in November Investor Conferences
Oct 22, 2026
Press release
Ligand to Host Investor Day on December 8, 2026
Ligand to Host Investor Day on December 8, 2026...
Oct 15, 2026
Earnings
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026...

SecBot reports

28 filings · 1 press release · 4 bullish · 0 bearish · 2 mixed · 22 neutral
All LGND filing & press-release reports (29)